Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer
Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from Intellia
Intellia Shares Updated Data On Gene Editing Durability In Rare Disease
Eight months after
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
Barchart
MarketBeat
Inverse
Medical Daily
StockNews.com
Organisations
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
